249 related articles for article (PubMed ID: 36240473)
21. Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.
Nützinger J; Bum Lee J; Li Low J; Ling Chia P; Talisa Wijaya S; Chul Cho B; Min Lim S; Soo RA
Lung Cancer; 2023 Dec; 186():107385. PubMed ID: 37813015
[TBL] [Abstract][Full Text] [Related]
22. Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea.
Lee K; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Cancer Res Treat; 2020 Jan; 52(1):292-300. PubMed ID: 31345011
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Robichaux JP; Elamin YY; Tan Z; Carter BW; Zhang S; Liu S; Li S; Chen T; Poteete A; Estrada-Bernal A; Le AT; Truini A; Nilsson MB; Sun H; Roarty E; Goldberg SB; Brahmer JR; Altan M; Lu C; Papadimitrakopoulou V; Politi K; Doebele RC; Wong KK; Heymach JV
Nat Med; 2018 May; 24(5):638-646. PubMed ID: 29686424
[TBL] [Abstract][Full Text] [Related]
24. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
Willmore-Payne C; Holden JA; Layfield LJ
Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
[TBL] [Abstract][Full Text] [Related]
25. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC.
Baraibar I; Mezquita L; Gil-Bazo I; Planchard D
Crit Rev Oncol Hematol; 2020 Apr; 148():102906. PubMed ID: 32109716
[TBL] [Abstract][Full Text] [Related]
26. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
[TBL] [Abstract][Full Text] [Related]
27. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC.
Riess JW; Gandara DR; Frampton GM; Madison R; Peled N; Bufill JA; Dy GK; Ou SI; Stephens PJ; McPherson JD; Lara PN; Burich RA; Ross JS; Miller VA; Ali SM; Mack PC; Schrock AB
J Thorac Oncol; 2018 Oct; 13(10):1560-1568. PubMed ID: 29981927
[TBL] [Abstract][Full Text] [Related]
28. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.
Oxnard GR; Lo PC; Nishino M; Dahlberg SE; Lindeman NI; Butaney M; Jackman DM; Johnson BE; Jänne PA
J Thorac Oncol; 2013 Feb; 8(2):179-84. PubMed ID: 23328547
[TBL] [Abstract][Full Text] [Related]
29. Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.
Kosaka T; Tanizaki J; Paranal RM; Endoh H; Lydon C; Capelletti M; Repellin CE; Choi J; Ogino A; Calles A; Ercan D; Redig AJ; Bahcall M; Oxnard GR; Eck MJ; Jänne PA
Cancer Res; 2017 May; 77(10):2712-2721. PubMed ID: 28363995
[TBL] [Abstract][Full Text] [Related]
30. EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation.
Zhao R; Li J; Guo L; Xiang C; Chen S; Zhao J; Shao J; Zhu L; Ye M; Qin G; Chu T; Han Y
Target Oncol; 2024 Mar; 19(2):277-288. PubMed ID: 38416376
[TBL] [Abstract][Full Text] [Related]
31. Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea.
Byeon S; Kim Y; Lim SW; Cho JH; Park S; Lee J; Sun JM; Choi YL; Lee SH; Ahn JS; Park K; Ahn MJ
Cancer Res Treat; 2019 Apr; 51(2):623-631. PubMed ID: 30049203
[TBL] [Abstract][Full Text] [Related]
32. NSCLC and HER2: between lights and shadows.
Ricciardi GR; Russo A; Franchina T; Ferraro G; Zanghì M; Picone A; Scimone A; Adamo V
J Thorac Oncol; 2014 Dec; 9(12):1750-62. PubMed ID: 25247338
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer.
Wang L; Diao M; Zhang Z; Jiang M; Chen S; Zhao D; Liu Z; Zhou C
Lung Cancer; 2024 Jan; 187():107439. PubMed ID: 38113653
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors.
Bai Y; Liu X; Zheng L; Wang S; Zhang J; Xiong S; Zhang P; Jiao Z; Zhao G; Zhou C; Pang J; Xu Y; Ou Q; Mao Y; Zhang L
Neoplasia; 2023 Apr; 38():100888. PubMed ID: 36804751
[TBL] [Abstract][Full Text] [Related]
35. A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).
Ninomiya K; Hata T; Yoshioka H; Ohashi K; Bessho A; Hosokawa S; Ishikawa N; Yamasaki M; Shibayama T; Aoe K; Kozuki T; Harita S; Ueda Y; Murakami T; Fujimoto N; Yanai H; Toyooka S; Takata M; Hotta K; Kiura K;
Chest; 2019 Aug; 156(2):357-366. PubMed ID: 31072612
[TBL] [Abstract][Full Text] [Related]
36. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
Odintsov I; Makarem M; Nishino M; Bachert SE; Zhang T; LoPiccolo J; Paweletz CP; Gokhale PC; Ivanova E; Saldanha A; Rudin CM; Lockwood WW; Ladanyi M; Somwar R; Jänne PA; Sholl LM
J Thorac Oncol; 2024 May; 19(5):732-748. PubMed ID: 38154514
[TBL] [Abstract][Full Text] [Related]
37. Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma.
Zhao S; Fang W; Pan H; Yang Y; Liang Y; Yang L; Dong X; Zhan J; Wang K; Zhang L
J Thorac Oncol; 2020 Jun; 15(6):962-972. PubMed ID: 32036069
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and clinicopathological associations of HER2 expression in non-small cell lung cancer: a retrospective study in Jordanian patients.
Abu Al Karsaneh O; Al Anber A; ALQudah M; Al-Mustafa S; AlMa'aitah H; Sughayer M
Diagn Pathol; 2023 Jun; 18(1):75. PubMed ID: 37340403
[TBL] [Abstract][Full Text] [Related]
39. Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.
Sun S; Du W; Sun Q; Zhao X; Qin B; Shi D; Wan C; Wu Z
Cancer Med; 2021 Oct; 10(20):7360-7372. PubMed ID: 34599863
[TBL] [Abstract][Full Text] [Related]
40. Frequency and types of
Lemine Sow M; El Yacoubi H; Moukafih B; Balde S; Akimana G; Najem S; El Khoyaali S; Abahssain H; Chaibi A; Zeb Khan S; Trapani D; Benzekri A; Ghaouti M; Gamra L; Mestari A; Kettani F; Rahali Y; Mrabti H; Elghissassi I; Errihani H
Tumori; 2021 Aug; 107(4):335-340. PubMed ID: 33079008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
